However, previous studies have revealed the existence of a membrane AR that binds to androgens to activate rapid cell surface steroid physiological actions in prostate, breast, and bladder cancers via Bax, p53, and JNK expression, and MAPK/MMP9 intracellular signaling [9, 44–46]. This evidence concerns the gene TP53 and urinary bladder cancer.